Eupraxia Pharmaceuticals Inc. (EPRX) SEC filings

EPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 13, 2026Score 5/30

$8.15+0.34 (+4.35%)

Close on Nov 13, 2026Market cap $491.40MP/E –Yield –

SEC filings

40 of Eupraxia Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	6-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	6-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	6-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	6-K	Oct 22, 2026	Oct 22, 2026	SEC EDGAR
Current report	6-K	Oct 15, 2026	Oct 15, 2026	SEC EDGAR
Current report	6-K	Oct 9, 2026	Oct 9, 2026	SEC EDGAR
Current report	6-K	Sep 30, 2026	Sep 30, 2026	SEC EDGAR
Current report	6-K	Sep 8, 2026	Sep 8, 2026	SEC EDGAR
Current report	6-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	6-K	Aug 11, 2026	Aug 11, 2026	SEC EDGAR
Current report	6-K	Jul 15, 2026	Jul 15, 2026	SEC EDGAR
Current report	6-K	Jul 13, 2026	Jul 13, 2026	SEC EDGAR
Current report	6-K	Jul 7, 2026	Jul 7, 2026	SEC EDGAR
Current report	6-K	Jun 19, 2026	Jun 22, 2026	SEC EDGAR
Current report	6-K	Jun 18, 2026	May 29, 2026	SEC EDGAR
Current report	6-K	May 28, 2026	May 29, 2026	SEC EDGAR
Current report	6-K	May 28, 2026	May 28, 2026	SEC EDGAR
Current report	6-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	6-K	May 6, 2026	May 6, 2026	SEC EDGAR
Current report	6-K	May 5, 2026	May 5, 2026	SEC EDGAR
Current report	6-K	May 1, 2026	May 1, 2026	SEC EDGAR
Current report	6-K	Apr 22, 2026	Apr 22, 2026	SEC EDGAR
Current report	6-K	Apr 21, 2026	Apr 21, 2026	SEC EDGAR
Current report	6-K	Apr 14, 2026	Apr 15, 2026	SEC EDGAR
Current report	6-K	Apr 14, 2026	Apr 15, 2026	SEC EDGAR
Current report	6-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Annual report	40-F	Dec 31, 2025	Mar 13, 2026	SEC EDGAR
Current report	6-K	Feb 23, 2026	Mar 6, 2026	SEC EDGAR
Current report	6-K	Feb 19, 2026	Feb 20, 2026	SEC EDGAR
Current report	6-K	Feb 20, 2026	Feb 20, 2026	SEC EDGAR
Current report	6-K	Feb 19, 2026	Feb 19, 2026	SEC EDGAR
Current report	6-K	Feb 18, 2026	Feb 18, 2026	SEC EDGAR
Current report	6-K	Jan 8, 2026	Jan 8, 2026	SEC EDGAR
Current report	6-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Current report	6-K	Nov 4, 2025	Nov 4, 2025	SEC EDGAR
Current report	6-K	Sep 29, 2025	Oct 1, 2025	SEC EDGAR
Current report	6-K	Sep 29, 2025	Sep 29, 2025	SEC EDGAR
Current report	6-K	Sep 24, 2025	Sep 24, 2025	SEC EDGAR
Current report	6-K	Sep 23, 2025	Sep 23, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Eupraxia Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EPRX.

Compare: EPRX vs MSLE · EPRX vs RANI · EPRX vs XRTX · EPRX vs PBM · EPRX vs MNOV

Company	Revenue	Growth
RANI	$6.58M	+448.7%
MNOV	$935.72K	–
EPRX	$0	–
MSLE	–	–
XRTX	–	–
PBM	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Held by institutions: 41.1%
Auditor: KPMG LLP
SEC CIK: 1581178

Advertisement
300 × 250

See a number that looks wrong?